BMS files rolling submission for FDA approval of anticoagulant apixaban
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb, along with partner Pfizer, has initiated a rolling submission with the US FDA for the Factor Xa inhibitor apixaban based on the Phase III AVERROES trial, chief executive Lamberto Andreotti told analysts during the company's third-quarter earnings conference call.